A Nomogram for Preoperative Prediction of the Risk of Lymph Node Metastasis in Patients with Epithelial Ovarian Cancer

Objective: To develop a nomogram for predicting lymph node metastasis (LNM) in patients with epithelial ovarian cancer (EOC). Methods: Between December 2012 and August 2022, patients with EOC who received computed tomography (CT) and serological examinations and were treated with upfront staging or debulking surgery were included. Systematic pelvic and para-aortic lymphadenectomy was performed in all patients. Univariate and multivariate analysis was used to identify significant risk factors associated with LNM. A nomogram was then constructed to assess the risk of LNM, which was evaluated with respect to its area under the receiver operating characteristic curve (AUC), calibration, and clinical usefulness. Results: Of 212 patients enrolled in this study, 78 (36.8%) had positive LNs. The nomogram integrating CT-reported LN status, child-bearing status, tumour laterality, and stage showed good calibration and discrimination with an AUC of 0.775, significantly improving performance over the CT results (0.699, p = 0.0002) with a net reclassification improvement of 0.593 (p < 0.001) and integrated discrimination improvement of 0.054 (p < 0.001). The decision curve analysis showed the nomogram was of clinical use. Conclusions: A nomogram was constructed and internally validated, which may act as a decision aid in patients with EOC being considered for systemic lymphadenectomy.

[1]  Li Zhang,et al.  Predictive value of indicator of CA125 combined with D-dimer (ICD) for lymph node metastasis in patients with ovarian cancer: A two center cohort study , 2022, Journal of Cancer.

[2]  R. Rouzier,et al.  Using a new diagnostic tool to predict lymph node metastasis in advanced epithelial ovarian cancer leads to simple lymphadenectomy decision rules: A multicentre study from the FRANCOGYN group , 2021, PloS one.

[3]  R. Rouzier,et al.  Preoperative CT or PET/CT to Assess Pelvic and Para-Aortic Lymph Node Status in Epithelial Ovarian Cancer? A Systematic Review and Meta-Analysis , 2021, Diagnostics.

[4]  F. Zhao,et al.  The Development and Validation of a CT-Based Radiomics Nomogram to Preoperatively Predict Lymph Node Metastasis in High-Grade Serous Ovarian Cancer , 2021, Frontiers in Oncology.

[5]  M. Koual,et al.  What can we learn from the 10 mm lymph node size cut-off on the CT in advanced ovarian cancer at the time of interval debulking surgery? , 2021, Gynecologic oncology.

[6]  He Huang,et al.  The impact of lymph node dissection on survival in patients with clinical early-stage ovarian cancer , 2021, Journal of gynecologic oncology.

[7]  Shanshan Cheng,et al.  Roles of CA125 in diagnosis, prediction, and oncogenesis of ovarian cancer. , 2021, Biochimica et biophysica acta. Reviews on cancer.

[8]  P. Widschwendter,et al.  CT Scan in the Prediction of Lymph Node Involvement in Ovarian Cancer – a Retrospective Analysis of a Tertiary Gyneco-Oncological Unit , 2020, Geburtshilfe und Frauenheilkunde.

[9]  J. Lang,et al.  Survival Analysis of Lymph Node Resection in Ovarian Cancer: A Population-Based Study , 2020, Frontiers in Oncology.

[10]  D. Matei,et al.  Supplemental online content for : NCCN Guidelines ® Insights : Ovarian Cancer , Version 1 . 2019 , 2019 .

[11]  D. Timmerman,et al.  ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease†. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  M. Gumus,et al.  Association of lymphadenectomy and survival in epithelial ovarian cancer. , 2019, Current problems in cancer.

[13]  Jae-Weon Kim,et al.  A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms , 2019, The New England journal of medicine.

[14]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[15]  C. Holman,et al.  Risk of high-grade serous ovarian cancer associated with pelvic inflammatory disease, parity and breast cancer. , 2018, Cancer epidemiology.

[16]  Cyril Ferdynus,et al.  Decision curve analysis: a technical note. , 2018, Annals of translational medicine.

[17]  A. Jemal,et al.  Ovarian cancer statistics, 2018 , 2018, CA: a cancer journal for clinicians.

[18]  G. Bogani,et al.  Assessing the risk of pelvic and para-aortic nodal involvement in apparent early-stage ovarian cancer: A predictors- and nomogram-based analyses. , 2017, Gynecologic oncology.

[19]  S. Houshmand,et al.  An update on the role of PET/CT and PET/MRI in ovarian cancer , 2017, European Journal of Nuclear Medicine and Molecular Imaging.

[20]  R. Zweemer,et al.  Surgical lymph node assessment in mucinous ovarian carcinoma staging: a systematic review and meta‐analysis , 2017, BJOG : an international journal of obstetrics and gynaecology.

[21]  Thomas A. Sellers,et al.  Epidemiology of ovarian cancer: a review , 2017, Cancer biology & medicine.

[22]  Jeong-Won Lee,et al.  Impact of lymphadenectomy on survival after recurrence in patients with advanced ovarian cancer without suspected lymph node metastasis. , 2016, Gynecologic oncology.

[23]  P. Konstantinopoulos,et al.  Prognostic implications of reproductive and lifestyle factors in ovarian cancer. , 2016, Gynecologic oncology.

[24]  San-Gang Wu,et al.  Risk factors for lymph node metastasis in ovarian cancer: Implications for systematic lymphadenectomy. , 2016, International journal of surgery.

[25]  D. Wallwiener,et al.  Relevance of pelvic and para-aortic node metastases in early-stage ovarian cancer. , 2014, Anticancer research.

[26]  D. Fischerová,et al.  Imaging techniques for the evaluation of ovarian cancer. , 2014, Best practice & research. Clinical obstetrics & gynaecology.

[27]  G. Yildirim,et al.  Can CA-125 Predict Lymph Node Metastasis in Epithelial Ovarian Cancers in Turkish Population? , 2014, Disease markers.

[28]  Jaime Prat,et al.  Staging classification for cancer of the ovary, fallopian tube, and peritoneum , 2014, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[29]  B. van Calster,et al.  PET/CT in the staging of patients with a pelvic mass suspicious for ovarian cancer. , 2013, Gynecologic oncology.

[30]  B. Rosner,et al.  Hormonal and Reproductive Risk Factors for Epithelial Ovarian Cancer by Tumor Aggressiveness , 2013, Cancer Epidemiology, Biomarkers & Prevention.

[31]  Figo Guidelines Staging classification for cancer of the ovary, fallopian tube, and peritoneum☆ , 2013 .

[32]  F. Raspagliesi,et al.  Systematic Para-aortic and Pelvic Lymphadenectomy in Early Stage Epithelial Ovarian Cancer: A Prospective Study , 2012, Annals of Surgical Oncology.

[33]  Zhao-xiang Gu,et al.  Computer tomography, magnetic resonance imaging, and positron emission tomography or positron emission tomography/computer tomography for detection of metastatic lymph nodes in patients with ovarian cancer: a meta-analysis. , 2012, European journal of radiology.

[34]  J. Prat Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features , 2012, Virchows Archiv.

[35]  T. Van Gorp,et al.  Lymph node metastasis in stages I and II ovarian cancer: a review. , 2011, Gynecologic oncology.

[36]  W. Cliby,et al.  Risk factors for lymph node metastasis in apparent early-stage epithelial ovarian cancer: implications for surgical staging. , 2011, Gynecologic oncology.

[37]  Ewout W Steyerberg,et al.  Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers , 2011, Statistics in medicine.

[38]  H. Haller,et al.  Frequency and Distribution of Lymph Node Metastases in Epithelial Ovarian Cancer: Significance of Serous Histology , 2010, International Journal of Gynecologic Cancer.

[39]  C. Coens,et al.  Surgical staging and treatment of early ovarian cancer: long-term analysis from a randomized trial. , 2010, Journal of the National Cancer Institute.

[40]  A. Reuss,et al.  Potential role of lymphadenectomy in advanced ovarian cancer: a combined exploratory analysis of three prospectively randomized phase III multicenter trials. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  H. Chung,et al.  Significance of preoperative serum CA‐125 levels in the prediction of lymph node metastasis in epithelial ovarian cancer , 2008, Acta obstetricia et gynecologica Scandinavica.

[42]  M. Gultekin,et al.  Metastatic lymph node number in epithelial ovarian carcinoma: does it have any clinical significance? , 2008, Gynecologic oncology.

[43]  M. Pencina,et al.  Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond , 2008, Statistics in medicine.

[44]  J. Magrina,et al.  Pelvic and aortic lymph node metastasis in epithelial ovarian cancer. , 2007, Gynecologic oncology.

[45]  P. Harter,et al.  Pattern and clinical predictors of lymph node metastases in epithelial ovarian cancer , 2006, International Journal of Gynecologic Cancer.

[46]  W. Cliby,et al.  Role of lymphadenectomy in the management of grossly apparent advanced stage epithelial ovarian cancer. , 2006, American journal of obstetrics and gynecology.

[47]  M. Piver Treatment of ovarian cancer at the crossroads: 50 years after single-agent melphalan chemotherapy. , 2006, Oncology.

[48]  V. Torri,et al.  Randomised study of systematic lymphadenectomy in patients with epithelial ovarian cancer macroscopically confined to the pelvis , 2006, British Journal of Cancer.

[49]  Y. Hirai,et al.  Lymph node metastasis in ovarian cancer: difference between serous and non-serous primary tumors. , 2005, Gynecologic oncology.

[50]  R. Rouzier,et al.  Lymph node involvement in epithelial ovarian cancer: analysis of 276 pelvic and paraaortic lymphadenectomies and surgical implications. , 2003, Journal of the American College of Surgeons.

[51]  M. Franchi,et al.  Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial. , 2003, Journal of the National Cancer Institute.

[52]  B J McNeil,et al.  Staging of advanced ovarian cancer: comparison of imaging modalities--report from the Radiological Diagnostic Oncology Group. , 2000, Radiology.

[53]  E. DeLong,et al.  Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. , 1988, Biometrics.